---
title: "Shanghai Micurx Pharmaceutical Co., Ltd. (688373.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688373.SH.md"
symbol: "688373.SH"
name: "Shanghai Micurx Pharmaceutical Co., Ltd."
industry: "Biotechnology"
---

# Shanghai Micurx Pharmaceutical Co., Ltd. (688373.SH)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | CN Market |
| Website | [www.micurxchina.com](https://www.micurxchina.com) |

## Company Profile

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a p...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:07.000Z

**Overall: D (0.63)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 75 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.85% |  |
| Net Profit YoY | 26.71% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 15.81 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.12B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 136.70M |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -83.12% | E |
| Profit Margin | -250.89% | E |
| Gross Margin | 85.05% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.85% | B |
| Net Profit YoY | 26.71% | B |
| Total Assets YoY | -25.12% | E |
| Net Assets YoY | -54.63% | E |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -39.86% | D |
| OCF YoY | 13.85% | B |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.16 | D |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 64.57% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Micurx Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-83.12%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-250.89%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "85.05%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "13.85%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "26.71%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-25.12%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-54.63%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-39.86%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "13.85%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.16",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "64.57%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BeOne Medicines (SH.688235) | C | A | B | C | A | B |
| 02 | Gan & Lee (SH.603087) | B | B | D | A | B | B |
| 03 | Sunshine Guojian Pharmaceutical (SH.688336) | A | B | D | B | C | B |
| 04 | Biocytogen (SH.688796) | A | A | C | D | B | B |
| 05 | BTBP (SH.600161) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -12.02 | 45/83 | - | - | - |
| PB | 15.81 | 74/83 | 16.67 | 14.92 | 10.32 |
| PS (TTM) | 30.15 | 75/83 | 37.89 | 31.81 | 30.00 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-03-23T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.28 |

## References

- [Company Overview](https://longbridge.com/en/quote/688373.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688373.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688373.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.